SELLAS Life Sciences stock experienced a dramatic surge of more than 200%, with shares trading above $20 on November 17 after the company announced positive Phase 3 trial results for its cancer vaccine candidate.
The rally was triggered by successful topline data from the REGAL trial, which evaluated galinpepimut-S (GPS) as a maintenance treatment for acute myeloid leukemia (AML) patients who had achieved a second or later remission but were unable to undergo stem-cell transplant.
Trial Results Meet Primary Endpoint
GPS met its primary endpoint of overall survival, demonstrating a 41% reduction in the risk of death compared with the control treatment. Patients receiving the experimental vaccine recorded a median overall survival of 24 months, versus 14.7 months in the control group.
The trial achieved a hazard ratio of 0.59 with a p-value of 0.035, indicating statistical significance. The treatment showed no new safety signals, with side effects reported as mostly mild to moderate.
The results are noteworthy given that AML is an aggressive blood cancer with limited treatment options for patients whose disease returns after initial therapy. GPS is designed to train the immune system to recognize and attack leukemia cells expressing the WT1 protein.
Regulatory Path and Timeline
SELLAS plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy. The company is preparing for a Biologics License Application submission in the first half of 2027, though GPS remains experimental and not yet approved for commercial use.
Pipeline Progress
Beyond GPS, SELLAS is advancing SLS009, an investigational CDK9 inhibitor in clinical development for AML. The company had indicated that preliminary topline data from its Phase 2 program were expected in the fourth quarter of 2026.
Stock Price Movement
SLS stock rose from its previous close of $7.47 to trade above $20 during the November 17 session, with an intraday high near $24.89. Key resistance levels are identified at $24–$25, while near-term support is noted at $16.70 and the $10–$11 region.


